Novo Nordisk's raised forecast fails to change the debate over its obesity business

Novo Nordisk raised its forecast for its obesity business, anchored by Ozempic. Yet according to CNBC, Wall Street remains skeptical the company can sustain growth as competition from Eli Lilly intensifies.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton